Phoremost

We are partnering with PhoreMost Limited,The logos of POLARISqb and Phoremost a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, today announced a collaboration to study oncology targets currently considered undruggable.

 

In this partnership, POLARISqb Tachyon™ quantum computing platform will be used to scan billions of molecules from a large chemical space, to find novel molecular drugs, based on the information obtained from PhoreMost’s SITESEEKER® phenotypic screening platform. Together, this partnership aims to discover and develop the next generation of oncology therapies.

 

PhoreMost’s novel target-identification platform, SITESEEKER, rapidly identifies unexpected or “cryptic” druggable sites across the entire genome, within targets previously considered undruggable, using the inherent shape diversity and disease functionality of PROTEINi® (protein interference) protein-fragment libraries in live cells. POLARISqb has built the first ever drug discovery platform using a quantum computer, Tachyon, which has the potential to drastically shorten the drug discovery process. By utilizing the increased power of quantum computers, POLARISqb is able to perform combinatorial optimizations in minutes that would take classical supercomputers months or even years to complete, leading to reduced drug development timelines and more efficient research.
Dr. Chris Torrance, CEO of Foremost“This partnership represents the ultimate ambition for any collaboration between biology and technology, where the full diversity of newly identified druggable disease targets generated by biological PROTEINi shape-libraries can now be married to the most logical and rapid method of finding small-molecule drugs to them. This best-in-class intersection of biotech and AI is going to be an exciting and transformative milestone for the entire pharmaceutical industry.”  
-Chris Torrance, CEO, Phoremost

 

 

Ready to work with us?

Contact us using the form below if you are interested in finding out how we might be able to revolutionize your drug discovery processes.